Literature DB >> 17545278

The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro.

John Yates1, Flavia Rovis, Peter Mitchell, Behdad Afzali, J Y-S Tsang, Marina Garin, R I Lechler, Giovanna Lombardi, O A Garden.   

Abstract

CD4+ CD25+ regulatory T cells (Tregs) have far-reaching immunotherapeutic applications, the realization of which will require a greater understanding of the factors influencing their function and phenotype during ex vivo manipulation. In murine models, IL-2 plays an important role in both the maintenance of a functional Treg population in vivo and the activation of suppression in vitro. We have found that IL-2 maintains optimal function of human CD4+ CD25+ Tregs in vitro and increases expression of both forkhead box protein 3, human nomenclature (FOXP3) and the distinctive markers CD25, cytotoxic T lymphocyte antigen-4 (CTLA-4) and glucocorticoid-induced tumor necrosis factor receptor superfamily member number 18 (GITR). Although IL-2 reduced spontaneous apoptosis of Tregs, this property alone could not account for the optimal maintenance of the regulatory phenotype. The inhibition of phosphatidylinositol 3-kinase (PI3K) signaling by LY294002, a chemical inhibitor of PI3K, abolished the maintenance of maximal suppressive potency by IL-2, yet had no effect on the up-regulation of FOXP3, CD25, CTLA-4 and GITR. Other common gamma chain (gammac) cytokines-IL-4, IL-7 and IL-15-had similar properties, although IL-4 showed a unique lack of effect on the expression of FOXP3 or Treg markers despite maintaining maximal regulatory function. Taken together, our data suggest a model in which the gammac cytokines IL-2, IL-4, IL-7 and IL-15 maintain the optimal regulatory function of human CD4+ CD25+ T cells in a PI3K-dependent manner, offering new insight into the effective manipulation of Tregs ex vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545278     DOI: 10.1093/intimm/dxm047

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  33 in total

Review 1.  Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6.

Authors:  Svetlana Chapoval; Preeta Dasgupta; Nicolas J Dorsey; Achsah D Keegan
Journal:  J Leukoc Biol       Date:  2010-03-24       Impact factor: 4.962

2.  Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells.

Authors:  S Alice Long; Jane H Buckner
Journal:  J Autoimmun       Date:  2008-03-03       Impact factor: 7.094

3.  Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.

Authors:  William H D Hallett; Erik Ames; Maite Álvarez; Isabel Barao; Patricia A Taylor; Bruce R Blazar; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

4.  Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.

Authors:  Serena K Perna; Biagio De Angelis; Daria Pagliara; Sayyeda T Hasan; Lan Zhang; Aruna Mahendravada; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Gianpietro Dotti; Barbara Savoldo
Journal:  Clin Cancer Res       Date:  2012-11-13       Impact factor: 12.531

Review 5.  Induced and natural regulatory T cells in the development of inflammatory bowel disease.

Authors:  Christopher G Mayne; Calvin B Williams
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

Review 6.  Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.

Authors:  Jon E Arnason; Jennifer R Brown
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

7.  Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways.

Authors:  N A Zwang; R Zhang; S Germana; M Y Fan; W D Hastings; A Cao; L A Turka
Journal:  Am J Transplant       Date:  2016-05-23       Impact factor: 8.086

8.  Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development.

Authors:  Diana Milojevic; Khoa D Nguyen; Diane Wara; Elizabeth D Mellins
Journal:  Pediatr Rheumatol Online J       Date:  2008-12-01       Impact factor: 3.054

Review 9.  Regulatory T cells overturned: the effectors fight back.

Authors:  Lucy S K Walker
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

Review 10.  New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation.

Authors:  Lai Wei; Arian Laurence; John J O'Shea
Journal:  Semin Cell Dev Biol       Date:  2008-07-30       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.